{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:03:25Z","timestamp":1787015005508,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"s434","license":[{"start":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T00:00:00Z","timestamp":1186444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To determine the safety and effectiveness of long\u2010acting injectable risperidone (LAI\u2010ris) add\u2010on in bipolar patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method:\u2002<\/jats:bold>\n                    A 6\u2010month, open\u2010label, randomized, pilot trial enrolled 49 bipolar out\u2010patients who were taking a mood stabilizer and an atypical antipsychotic (AAP). Patients were maintained on a mood stabilizer and were randomized to continuation of their current AAP or switched to LAI\u2010ris treatment. Safety outcomes included adverse events and changes in vital signs, laboratory tests and extrapyramidal symptoms (EPS). Effectiveness measures included Clinical Global Impression\u2010Severity, scales assessing mania, depression, anxiety, resource utilization, quality of life, subject satisfaction with treatment, and time to intervention.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Twenty\u2010three subjects were randomized to LAI\u2010ris and 26 to oral AAP. There were no significant differences between the groups in adverse events, EPS change scores, weight or other safety measures. LAI\u2010ris group had significant reductions in symptoms as measured by changes in Clinical Global Impression\u2010Severity scores and Young Mania Rating Scale at endpoint relative to baseline and oral AAP group had reductions in Hamilton Anxiety Rating Scale scores relative to baseline but no significant differences were noted between the groups on any of the efficacy measures.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    LAI\u2010ris demonstrated similar effectiveness, safety and tolerability compared to oral AAP in this 6\u2003month pilot trial.\n                  <\/jats:p>","DOI":"10.1111\/j.1600-0447.2007.01059.x","type":"journal-article","created":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T05:09:06Z","timestamp":1186463346000},"page":"50-56","source":"Crossref","is-referenced-by-count":32,"title":["A 6\u2010month randomized open\u2010label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder"],"prefix":"10.1111","volume":"116","author":[{"given":"L. N.","family":"Yatham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,7]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00219.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2005.01.001"},{"key":"e_1_2_9_4_2","first-page":"A23","article-title":"Olanzapine and olanzapine\u2010fluoxetine combination (OFC) in the treatment of bipolar depression","volume":"17","author":"Tohen M","year":"2003","journal-title":"J Psychopharmacol"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"key":"e_1_2_9_6_2","first-page":"26","article-title":"Olanzapine\u2019s efficacy for relapse prevention in bipolar disorder: a randomized double\u2010blind placebo\u2010controlled 12\u2010month clinical trial","volume":"6","author":"Tohen M","year":"2004","journal-title":"Bipolar Disord"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1281"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200403000-00008"},{"key":"e_1_2_9_10_2","first-page":"S143","article-title":"Risperidone treatment of Bipolar Disorder: findings of a 6\u2010month open\u2010label study in Spain","volume":"3","author":"Vieta E","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.3.264"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.1r084.x"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0502"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.8.993"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.003"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.6.805"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-003-0428-3"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"e_1_2_9_19_2","first-page":"S236","article-title":"Long\u2010acting risperidone in young adults with schizophrenia and schizoaffective disorder","volume":"7","author":"Lasser R","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-946703"},{"key":"e_1_2_9_21_2","first-page":"192","article-title":"Bipolar disorder: 6\u2010months efficacy of risperidone injectable","volume":"6","author":"Medori R","year":"2005","journal-title":"World J Biol Psychiatry"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056515"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000231609.91144.00"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.05.008"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.2007.01059.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.2007.01059.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:31:40Z","timestamp":1695745900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.2007.01059.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,7]]},"references-count":23,"journal-issue":{"issue":"s434","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1600-0447.2007.01059.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.2007.01059.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,7]]}}}